Research and Markets - Global Antiviral Drugs Market to Grow at a CAGR of 9.48%, 2017-2021 with Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead Sciences & GlaxoSmithKline Leading the Market

DUBLIN, April 18, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Antiviral Drugs Market 2017-2021" report to their offering.

The global antiviral drugs market to grow at a CAGR of 9.48% during the period 2017-2021.

The report, Global Antiviral Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is technological advancements. The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective in nature. This technique will not only have a positive impact against viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above $100 and could be used to control an epidemic effectively, can now be produced at 1% of its original cost.

According to the report, one of the major drivers for this market is stockpiling by public healthcare agencies. The CDC estimates that government organizations such as the WHO are also taking initiatives to secure public health during future outbreak of viral diseases by increasing the antiviral drugs stock. The CDC manages the Strategic National Stockpile, which includes storage of bulk quantities of antiviral medications for public health emergencies.

Key vendors

• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
  

Other prominent vendors

• AbbVie
• Johnson & Johnson
• Merck
• Novartis
  

Key Topics Covered:

PART 01: Executive summary

PART 02: Research Methodology

PART 03: Introduction

PART 04: Disease Overview

PART 05: Market landscape

PART 06: Pipeline analysis

PART 07: Market segmentation by therapies

PART 08: Market segmentation by MOA

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Competitive Landscape

PART 14: Key vendor analysis

PART 15: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/djspnx/global_antiviral

Media Contact:

Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]